Chengdu Kanghua Biological Products
Chengdu · Founded 2004
About Chengdu Kanghua Biological Products
Kanghua Biological is a research and development, production, and operation of preventive biological products. The company's research and development, production base, SPF laboratory animal center, and high-tech bacterial and virus vaccine GMP production workshop occupy 30,000 square meters. Its existing product includes ACYW135 group Meningococcal Polysaccharide Vaccine, (trade name: Maicred) and Freeze-dried Rabies Vaccine for Human Use (Human Diploid Cells), (trade name: HDCV). It has been awarded the titles of "Postdoctoral Innovation Practice Base", "Sichuan Province Constructive Innovation Enterprise Cultivation Enterprise", "Sichuan Province Excellent Integrity Demonstration Unit" by the Personnel Department and the Science and Technology Department. It was founded in 2004 in Chengdu, Sichuan, China.
Company Facts
- Founded: 2004
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 501 – 1,000
- Total funding: $49.7M
- Funding stage: IPO
- Last round: Post-IPO Secondary (Sep 2024)
- Ticker: szse:300841
- Website: kangh.com
- Phone: (86) 028-84846555
Industries & Categories
Agriculture, Biotechnology, Life Science, Product Research
Social Profiles
Canonical: https://fsome.com/organization/chengdu-kanghua-biological-products-168994 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.